Combination Therapy with Biologic and Cholesterol-Lowering Agents

Introduction to Medications

• Etanercept, a TNF-alpha inhibitor, is used for inflammatory conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis, and its mechanism involves binding and inactivating TNF-alpha, reducing inflammation 1
• Common side effects of etanercept include injection site reactions, increased risk of infections, potential reactivation of latent tuberculosis, and a rare risk of demyelinating disorders 1
• Evolocumab, a PCSK9 inhibitor, is used to lower LDL cholesterol, with common side effects including back pain, nasopharyngitis, upper respiratory tract infection, influenza, and injection site reactions 2

Infection Risk and Monitoring

• Etanercept increases infection risk, especially when used with other immunosuppressants, and monitoring for signs of infection (fever, cough, chills) is recommended, as suggested by the American College of Chest Physicians 1
• Patients on etanercept should be watched for signs of infection, with a strength of evidence supported by the American College of Chest Physicians and British Journal of Dermatology guidelines 1, 3

Cardiovascular Considerations

• Etanercept has a black box warning regarding heart failure, though less concerning than with infliximab, according to the British Journal of Dermatology guidelines, with a moderate strength of evidence 3
• Evolocumab is beneficial for cardiovascular outcomes by reducing LDL cholesterol, and patients with pre-existing heart failure (NYHA class III or IV) should be monitored with caution, as recommended by the British Journal of Dermatology guidelines, with a high strength of evidence 3
• The following table summarizes the cardiovascular considerations:

Screening and Assessment

• Before starting combination therapy, screen for latent tuberculosis (TB test and chest X-ray) and check hepatitis serology, as etanercept should be avoided with active viral hepatitis, with a high strength of evidence supported by the American College of Chest Physicians and British Journal of Dermatology guidelines 1, 3
• Assess cardiovascular status, especially in patients with heart failure, according to the British Journal of Dermatology guidelines, with a moderate strength of evidence 3

Treatment Monitoring

• Monitor for signs of infection, and regularly assess liver function in patients with a history of viral hepatitis, as recommended by the Journal of the American Academy of Dermatology, with a high strength of evidence 1, 4
• Watch for neurological symptoms that could indicate demyelinating disorders, as recommended by the Journal of the American Academy of Dermatology, with a moderate strength of evidence 1, 4

Special Considerations

• Live vaccines should be avoided while on etanercept, as recommended by the American College of Chest Physicians, with a high strength of evidence 1
• Patients with severe heart failure (NYHA class III or IV) should avoid TNF inhibitors, according to the British Journal of Dermatology guidelines, with a moderate strength of evidence 3
• Discontinue etanercept if serious infection develops, as recommended by the Journal of the American Academy of Dermatology, with a high strength of evidence 4
• Patients with a history of demyelinating disorders should avoid TNF inhibitors, according to the Journal of the American Academy of Dermatology guidelines, with a moderate strength of evidence 4
• Back pain is a possible side effect of evolocumab, and healthcare providers should inform patients, monitor for back pain, and consider simple analgesics for symptom management, as recommended by the American College of Cardiology guidelines, with a moderate strength of evidence 2